Last reviewed · How we verify

Latanoprost, 24-hour intraocular pressure monitoring

Aristotle University Of Thessaloniki · FDA-approved active Small molecule Quality 2/100

Latanoprost, 24-hour intraocular pressure monitoring is a Small molecule drug developed by Aristotle University Of Thessaloniki. It is currently FDA-approved. Also known as: Ganfort, Xalatan.

At a glance

Generic nameLatanoprost, 24-hour intraocular pressure monitoring
Also known asGanfort, Xalatan
SponsorAristotle University Of Thessaloniki
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Latanoprost, 24-hour intraocular pressure monitoring

What is Latanoprost, 24-hour intraocular pressure monitoring?

Latanoprost, 24-hour intraocular pressure monitoring is a Small molecule drug developed by Aristotle University Of Thessaloniki.

Who makes Latanoprost, 24-hour intraocular pressure monitoring?

Latanoprost, 24-hour intraocular pressure monitoring is developed and marketed by Aristotle University Of Thessaloniki (see full Aristotle University Of Thessaloniki pipeline at /company/aristotle-university-of-thessaloniki).

Is Latanoprost, 24-hour intraocular pressure monitoring also known as anything else?

Latanoprost, 24-hour intraocular pressure monitoring is also known as Ganfort, Xalatan.

What development phase is Latanoprost, 24-hour intraocular pressure monitoring in?

Latanoprost, 24-hour intraocular pressure monitoring is FDA-approved (marketed).

Related